Dynavax to Present at William Blair's 45th Annual Growth Stock Conference

5/28/25 4:10:00 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $DVAX alert in real time by email

EMERYVILLE, Calif., May 28, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at William Blair's 45th Annual Growth Stock Conference on Tuesday, June 3rd at 2:40 p.m. CT.

The presentations will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations.

About Dynavax

Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and the United Kingdom for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. For more information about our marketed products and development pipeline, visit www.dynavax.com.

For Investors/Media:

Paul Cox

[email protected]

510-665-0499

Nicole Arndt

[email protected]

510-665-7264

View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-present-at-william-blairs-45th-annual-growth-stock-conference-302467588.html

SOURCE Dynavax Technologies

Get the next $DVAX alert in real time by email

Recent Analyst Ratings for

$DVAX

Date	Price Target	Rating	Analyst
2/11/2025	$15.00 → $12.00	Neutral → Sell	Goldman
2/1/2024	$20.00	Neutral	Goldman
9/27/2022	$22.00	Mkt Outperform	JMP Securities
1/6/2022	$38.00	Buy	Goldman
12/29/2021	$23.00 → $28.00	Buy	HC Wainwright & Co.
8/31/2021	$20.00 → $23.00	Buy	HC Wainwright & Co.
8/6/2021	$19.00	Buy	Goldman Sachs
8/5/2021	$16.00 → $20.00	Buy	HC Wainwright & Co.

More analyst ratings

Dynavax to Present at William Blair's 45th Annual Growth Stock Conference

Chat with this insight

Recent Analyst Ratings for
$DVAX

$DVAX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Silvernail Lauren P was granted 1,439 shares, increasing direct ownership by 17% to 10,075 units (SEC Form 4)

Director Kisner Daniel L was granted 5,758 shares, increasing direct ownership by 33% to 23,329 units (SEC Form 4)

Director Myers Scott Dunseth was granted 5,758 shares, increasing direct ownership by 23% to 31,204 units (SEC Form 4)

$DVAX
Press Releases

Fastest customizable press release news feed in the world

Dynavax Stockholders Elect All Dynavax Director Nominees at 2025 Annual Meeting

Deep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final Perspectives on Why Change is Needed in the Boardroom

Dynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual Meeting

$DVAX
SEC Filings

Dynavax Technologies Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders

SEC Form DEFA14A filed by Dynavax Technologies Corporation

SEC Form DEFA14A filed by Dynavax Technologies Corporation

$DVAX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Dynavax downgraded by Goldman with a new price target

Goldman initiated coverage on Dynavax with a new price target

JMP Securities initiated coverage on Dynavax with a new price target

Dynavax to Present at William Blair's 45th Annual Growth Stock Conference

Chat with this insight

Recent Analyst Ratings for $DVAX

$DVAX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Silvernail Lauren P was granted 1,439 shares, increasing direct ownership by 17% to 10,075 units (SEC Form 4)

Director Kisner Daniel L was granted 5,758 shares, increasing direct ownership by 33% to 23,329 units (SEC Form 4)

Director Myers Scott Dunseth was granted 5,758 shares, increasing direct ownership by 23% to 31,204 units (SEC Form 4)

$DVAX Press Releases

Fastest customizable press release news feed in the world

Dynavax Stockholders Elect All Dynavax Director Nominees at 2025 Annual Meeting

Deep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final Perspectives on Why Change is Needed in the Boardroom

Dynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual Meeting

$DVAX SEC Filings

Dynavax Technologies Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders

SEC Form DEFA14A filed by Dynavax Technologies Corporation

SEC Form DEFA14A filed by Dynavax Technologies Corporation

$DVAX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Dynavax downgraded by Goldman with a new price target

Goldman initiated coverage on Dynavax with a new price target

JMP Securities initiated coverage on Dynavax with a new price target

Recent Analyst Ratings for
$DVAX

$DVAX
Insider Trading

$DVAX
Press Releases

$DVAX
SEC Filings

$DVAX
Analyst Ratings